Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRK2 | P25098 | 15/20 | 0.69 |
| ▸ | ROCK1 | Q13464 | 12/20 | 0.69 |
| ▸ | GRK5 | P34947 | 11/20 | 0.69 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.69 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.69 |
| ▸ | GRK1 | Q15835 | 5/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2570905 | 0.87 | GRK2 (0.68) | GRK2ROCK1GRK5RPS6KB1RPS6KA1 | |
| SCHEMBL2568044 | 0.87 | GRK2 (0.74) | GRK2ROCK1GRK5RPS6KB1RPS6KA1 | |
| SCHEMBL2571019 | 0.87 | GRK2 (0.68) | GRK2ROCK1GRK5RPS6KB1RPS6KA1 | |
| SCHEMBL2570138 | 0.87 | GRK2 (0.74) | GRK2ROCK1GRK5RPS6KB1RPS6KA1 | |
| SCHEMBL2568281 | 0.86 | GRK2 (0.74) | GRK2ROCK1GRK5RPS6KB1RPS6KA1 | |
| SCHEMBL2565505 | 0.85 | GRK2 (0.82) | GRK2ROCK1GRK5RPS6KB1RPS6KA1 | |
| SCHEMBL12162592 | 0.85 | GRK2 (0.67) | GRK2ROCK1GRK5RPS6KB1RPS6KA1 | |
| SCHEMBL2569513 | 0.84 | ROCK1 (0.64) | GRK2ROCK1GRK5RPS6KB1RPS6KA1 | |
| SCHEMBL2566515 | 0.84 | GRK2 (0.72) | GRK2ROCK1GRK5RPS6KB1RPS6KA1 | |
| SCHEMBL2570874 | 0.83 | GRK2 (0.76) | GRK2ROCK1GRK5RPS6KB1RPS6KA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633740-B1 | 5-(ACYLAMINO)INDAZOLE DERIVATIVES AS KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-11-09 | — | — | EP | claimed |
| US-7560467-B2 | Indazolo-tetrahydropyrimidine-carboxamide derivative kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-14 | — | — | US | claimed |
| US-20070099944-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2007-05-03 | — | — | US | claimed |
| EP-1633740-B1 | 5-(ACYLAMINO)INDAZOLE DERIVATIVES AS KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-11-09 | — | — | EP | disclosed |
| EP-1633740-B1 | 5-(ACYLAMINO)INDAZOLE DERIVATIVES AS KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-11-09 | — | — | EP | disclosed |
| US-7560467-B2 | Indazolo-tetrahydropyrimidine-carboxamide derivative kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-14 | — | — | US | disclosed |
| US-7560467-B2 | Indazolo-tetrahydropyrimidine-carboxamide derivative kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-14 | — | — | US | disclosed |
| US-7560467-B2 | Indazolo-tetrahydropyrimidine-carboxamide derivative kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-14 | — | — | US | disclosed |
| EP-1633740-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2008-11-19 | — | — | EP | disclosed |
| US-20070099944-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2007-05-03 | — | — | US | disclosed |
| US-20070099944-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2007-05-03 | — | — | US | disclosed |
| US-20070099944-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2007-05-03 | — | — | US | disclosed |
| EP-1633740-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004112719-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099944-A1 | Chemical compounds | ROCK1, ROCK2, CIT | GRK2 165/4885ROCK1 1/4885GRK5 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.